Long-lasting severe anemia following treatment with natalizumab for relapsing-remitting multiple sclerosis: a case report.
Anemia
Inhibited maturation
Multiple sclerosis
Natalizumab
VLA-4
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
received:
10
01
2024
accepted:
15
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
12
5
2024
Statut:
epublish
Résumé
Natalizumab is a monoclonal antibody used to treat patients with relapsing-remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when natalizumab is stopped. Here, we describe a case of a young woman with severe and especially long lasting anemia associated with treatment with natalizumab, persisting up to a year after treatment was stopped. A 24 year-old Caucasian woman with relapsing-remitting multiple sclerosis developed severe transfusion dependent anemia after 27 infusions with natalizumab, which was her first and only treatment for her multiple sclerosis. Extensive hematologic diagnostics did not reveal any malignant cause or any other plausible non-malignant cause for her anemia. The bone marrow was found to be hypercellular, with a maturation arrest of the erythropoiesis and with grade 1-2 fibrosis. No specific treatment for the anemia was given. The hemoglobin level showed signs of spontaneous increase after nearly one year after natalizumab was discontinued. Severe anemia can be caused by treatment with natalizumab. This case adds information to the few other similar reported cases, demonstrating the potential duration of the anemia, as well as detailed description of hematologic findings. The mechanism is most likely due to inhibition of α4 subunit of the α4β1-integrin, which is present on both lymphocytes and erythroid precursor cells.
Sections du résumé
BACKGROUND
BACKGROUND
Natalizumab is a monoclonal antibody used to treat patients with relapsing-remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when natalizumab is stopped. Here, we describe a case of a young woman with severe and especially long lasting anemia associated with treatment with natalizumab, persisting up to a year after treatment was stopped.
CASE PRESENTATION
METHODS
A 24 year-old Caucasian woman with relapsing-remitting multiple sclerosis developed severe transfusion dependent anemia after 27 infusions with natalizumab, which was her first and only treatment for her multiple sclerosis. Extensive hematologic diagnostics did not reveal any malignant cause or any other plausible non-malignant cause for her anemia. The bone marrow was found to be hypercellular, with a maturation arrest of the erythropoiesis and with grade 1-2 fibrosis. No specific treatment for the anemia was given. The hemoglobin level showed signs of spontaneous increase after nearly one year after natalizumab was discontinued.
CONCLUSION
CONCLUSIONS
Severe anemia can be caused by treatment with natalizumab. This case adds information to the few other similar reported cases, demonstrating the potential duration of the anemia, as well as detailed description of hematologic findings. The mechanism is most likely due to inhibition of α4 subunit of the α4β1-integrin, which is present on both lymphocytes and erythroid precursor cells.
Identifiants
pubmed: 38736000
doi: 10.1186/s13256-024-04562-8
pii: 10.1186/s13256-024-04562-8
doi:
Substances chimiques
Natalizumab
0
Immunologic Factors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Informations de copyright
© 2024. The Author(s).
Références
von Andrian UH, Engelhardt B. α4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68–72.
doi: 10.1056/NEJMe020157
Bachofner A. Natalizumab: hyporegenerative anaemia secondary to erythroid maturation arrest: case report. Reactions weekly. 2019;1748(1):371–371.
doi: 10.1007/s40278-019-60287-4
Mansoor S, et al. Natalizumab-induced hyporegenerative anaemia and leukopenia: a case report. Egypt J Neurol Psychiatry Neurosurg. 2020;56(1):6.
doi: 10.1186/s41983-019-0143-2
Monteleone F, et al. Reversible hyporegenerative anemia during natalizumab treatment. Mult Scler. 2015;21(2):257–8.
doi: 10.1177/1352458514546516
pubmed: 25186208
Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015;84(8):861–861.
doi: 10.1212/01.wnl.0000461938.49936.52
pubmed: 25713115
Simone AM, et al. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2014;83(4):374–5.
doi: 10.1212/WNL.0000000000000614
pubmed: 24944259
Aslinia F, Mazza JJ, Yale SH. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res. 2006;4(3):236–41.
doi: 10.3121/cmr.4.3.236
pubmed: 16988104
pmcid: 1570488
Zeidan AM, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
doi: 10.1016/j.blre.2018.09.001
pubmed: 30314642
Vergara-Lluri MEMD, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014;45(11):2183–91.
doi: 10.1016/j.humpath.2014.07.017
pubmed: 25282037
Midaglia L, Rodriguez Ruiz M, Muñoz-García D. Severe haematological complications during treatment with natalizumab. Mult Scler. 2012;18(11):1644–6.
doi: 10.1177/1352458512442262
pubmed: 22438058
Rivero NL. Natalizumab: autoimmune haemolytic anaemia: case report. Reactions weekly. 2013;1363(1):30–30.
Parker V, Tormey CA. The direct antiglobulin test: indications, interpretation, and pitfalls. Arch Pathol Lab Med. 2017;141(2):305–10.
doi: 10.5858/arpa.2015-0444-RS
pubmed: 28134589
Pozo AL, Godfrey EM, Bowles KM. Splenomegaly: investigation, diagnosis and management. Blood Rev. 2009;23(3):105–11.
doi: 10.1016/j.blre.2008.10.001
pubmed: 19062140
Chisaka H, et al. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol. 2003;13(6):347–59.
doi: 10.1002/rmv.395
pubmed: 14625883
Godano E, et al. Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy. Ital J Pediatr. 2021;47(1):69–69.
doi: 10.1186/s13052-021-01025-4
pubmed: 33757559
pmcid: 7987111
Rosemblatt M, et al. Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature human erythroblastic precursor cells. J Clin Invest. 1991;87(1):6–11.
doi: 10.1172/JCI115002
pubmed: 1824634
pmcid: 294977
Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood. 2008;112(3):470–8.
doi: 10.1182/blood-2008-03-077883
pubmed: 18650462
pmcid: 2481536
Muralidharan KK, et al. Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol. 2017;57(8):1017–30.
doi: 10.1002/jcph.894
pubmed: 28398628
EMA, Tysabri : EPAR - Product Information. 2022, EMA. p. 76.
Foley JF, et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord. 2019;31:65–71.
doi: 10.1016/j.msard.2019.03.017
pubmed: 30939392
Serra López-Matencio JM, et al. Evaluation of Natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses. Front Neurol. 2021;12:716548–716548.
doi: 10.3389/fneur.2021.716548
pubmed: 34690914
pmcid: 8529019
Derfuss T, et al. α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurology. 2017;4(5): e388.
Plavina T, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89(15):1584–93.
doi: 10.1212/WNL.0000000000004485
pubmed: 28916537
pmcid: 5634662
Kuter DJ, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–62.
doi: 10.1111/j.1365-2141.2007.06807.x
pubmed: 17910625